Literature DB >> 18514574

Revival of CD8+ Treg-mediated suppression.

Trevor R F Smith1, Vipin Kumar.   

Abstract

Despite their first recognition almost 40 years ago, CD8(+) 'suppressor' T cells remain poorly characterized. Recent studies of these lymphocytes, now popularly referred to as regulatory CD8(+) T cells (CD8(+) Tregs), have helped clarify their important role in the regulation of autoimmune disease. Here, we review progress related to the identification, phenotype and function of CD8(+) Tregs. We also focus on a newly described subset, CD8alphaalpha(+)TCRalphabeta(+) Tregs, which in mice recognize a T-cell receptor-derived peptide in the context of the class Ib major histocompatibility complex molecule Qa-1. These Tregs target only activated T cells and complement the suppression provided by CD4(+)Foxp3(+) Tregs. Investigations leading to the detailed identification, expansion, maintenance and function of CD8alphaalpha(+) Tregs should result in new therapeutic strategies for human inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514574     DOI: 10.1016/j.it.2008.04.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  83 in total

Review 1.  Mechanisms of self-nonself discrimination and possible clinical relevance.

Authors:  Carolin Daniel; Jens Nolting; Harald von Boehmer
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

2.  CD8+CD122+CD49dlow regulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity.

Authors:  Kazuyuki Akane; Seiji Kojima; Tak W Mak; Hiroshi Shiku; Haruhiko Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-11       Impact factor: 11.205

3.  Eomesodermin(lo) CTLA4(hi) Alloreactive CD8+ Memory T Cells Are Associated With Prolonged Renal Transplant Survival Induced by Regulatory Dendritic Cell Infusion in CTLA4 Immunoglobulin-Treated Nonhuman Primates.

Authors:  Mohamed B Ezzelarab; Lien Lu; Hao Guo; Alan F Zahorchak; William F Shufesky; David K C Cooper; Adrian E Morelli; Angus W Thomson
Journal:  Transplantation       Date:  2016-01       Impact factor: 4.939

4.  Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis.

Authors:  Nathan R York; Jason P Mendoza; Sterling B Ortega; Andrew Benagh; Andrew F Tyler; Mihail Firan; Nitin J Karandikar
Journal:  J Autoimmun       Date:  2010-02-20       Impact factor: 7.094

5.  Comeback kids: CD8(+) suppressor T cells are back in the game.

Authors:  Luc Van Kaer
Journal:  J Clin Invest       Date:  2010-09-27       Impact factor: 14.808

6.  The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE.

Authors:  Alla L Zozulya; Sonja Ortler; Zsuzsanna Fabry; Matyas Sandor; Heinz Wiendl
Journal:  Eur J Immunol       Date:  2009-06       Impact factor: 5.532

7.  Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.

Authors:  Khrishen Cunnusamy; Ethan J Baughman; Jorge Franco; Sterling B Ortega; Sushmita Sinha; Parul Chaudhary; Benjamin M Greenberg; Elliot M Frohman; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2014-03-20       Impact factor: 3.969

Review 8.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

9.  ANALYSIS OF DENDRITIC CELL STIMULATION UTILIZING A MULTI-FACETED NANOPOLYMER DELIVERY SYSTEM AND THE IMMUNE MODULATOR 1-METHYL TRYPTOPHAN.

Authors:  Kevin P Nikitczuk; Edmund C Lattime; Rene S Schloss; Martin L Yarmush
Journal:  Nano Life       Date:  2010-09-01

Review 10.  Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice.

Authors:  Brian J Skaggs; Ram Pyare Singh; Bevra H Hahn
Journal:  Hum Immunol       Date:  2008-09-24       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.